JP2006508983A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508983A5 JP2006508983A5 JP2004553785A JP2004553785A JP2006508983A5 JP 2006508983 A5 JP2006508983 A5 JP 2006508983A5 JP 2004553785 A JP2004553785 A JP 2004553785A JP 2004553785 A JP2004553785 A JP 2004553785A JP 2006508983 A5 JP2006508983 A5 JP 2006508983A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- carrier
- magnesium stearate
- thalidomide
- single dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 10
- 235000019359 magnesium stearate Nutrition 0.000 claims 5
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229960003433 thalidomide Drugs 0.000 claims 3
- 229920002261 Corn starch Polymers 0.000 claims 2
- 239000008120 corn starch Substances 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42601602P | 2002-11-14 | 2002-11-14 | |
| US60/426,016 | 2002-11-14 | ||
| PCT/US2003/036620 WO2004045579A2 (en) | 2002-11-14 | 2003-11-13 | Pharmaceutical compositions and dosage forms of thalidomide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009119084A Division JP4927905B2 (ja) | 2002-11-14 | 2009-05-15 | サリドマイドの医薬組成物および剤形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006508983A JP2006508983A (ja) | 2006-03-16 |
| JP2006508983A5 true JP2006508983A5 (https=) | 2006-04-27 |
| JP5269280B2 JP5269280B2 (ja) | 2013-08-21 |
Family
ID=32326306
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004553785A Expired - Lifetime JP5269280B2 (ja) | 2002-11-14 | 2003-11-13 | サリドマイドの医薬組成物および剤形 |
| JP2009119084A Expired - Fee Related JP4927905B2 (ja) | 2002-11-14 | 2009-05-15 | サリドマイドの医薬組成物および剤形 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009119084A Expired - Fee Related JP4927905B2 (ja) | 2002-11-14 | 2009-05-15 | サリドマイドの医薬組成物および剤形 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7230012B2 (https=) |
| EP (2) | EP2277512A3 (https=) |
| JP (2) | JP5269280B2 (https=) |
| KR (1) | KR100671366B1 (https=) |
| CN (2) | CN101816626A (https=) |
| AU (2) | AU2003290982C1 (https=) |
| BR (1) | BR0316240A (https=) |
| CA (1) | CA2505964C (https=) |
| DK (1) | DK1562556T3 (https=) |
| ES (1) | ES2403142T3 (https=) |
| IL (1) | IL168585A (https=) |
| MX (1) | MXPA05005162A (https=) |
| NZ (1) | NZ540545A (https=) |
| PT (1) | PT1562556E (https=) |
| SI (1) | SI1562556T1 (https=) |
| TW (2) | TWI377062B (https=) |
| WO (1) | WO2004045579A2 (https=) |
| ZA (1) | ZA200503927B (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
| US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
| US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
| US20110008327A1 (en) | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
| US20100028339A1 (en) | 2004-03-29 | 2010-02-04 | Cheng Jin Q | Compositions including triciribine and trastuzumab and methods of use thereof |
| US20100009928A1 (en) * | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and taxanes and methods of use thereof |
| US20100173864A1 (en) | 2004-03-29 | 2010-07-08 | Cheng Jin Q | Compositions including triciribine and one or more platinum compounds and methods of use thereof |
| US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
| MXPA06011219A (es) | 2004-03-29 | 2007-05-08 | Univ South Florida | Tratamiento efectivo de tumores y cancer con triciribina y compuestos relacionados. |
| US7534381B2 (en) * | 2005-09-14 | 2009-05-19 | Isp Investments Inc. | Process and apparatus for forming agglomerates of a powder composition of an active and binder |
| CN1870631B (zh) * | 2005-11-11 | 2010-04-14 | 华为技术有限公司 | 媒体网关的门控方法 |
| JP5546860B2 (ja) * | 2006-08-16 | 2014-07-09 | ノバルティス アーゲー | 高結晶性治療化合物の固体分散体を製造するための方法 |
| RU2009121838A (ru) * | 2006-11-10 | 2010-12-20 | Альфаптозе ГмбХ (DE) | Пероральная лекарственая форма, содержащая соединения тризамещенного глицерина |
| US20090137631A1 (en) * | 2007-11-22 | 2009-05-28 | National Yang-Ming University | Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression |
| BRPI1007855B1 (pt) | 2009-05-19 | 2020-03-10 | Celgene Corporation | Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona |
| KR101369936B1 (ko) * | 2011-12-28 | 2014-03-06 | 연세대학교 산학협력단 | 탈리도마이드를 포함하는 루프스 신염 치료용 약학 조성물 |
| JP5087182B1 (ja) | 2012-06-13 | 2012-11-28 | クリニプロ株式会社 | 吸入用パウダーの製造方法 |
| AU2015210999A1 (en) | 2014-01-29 | 2016-07-21 | Otsuka Pharmaceutical Co., Ltd. | Device-based risk management of a therapeutic |
| CN106137986B (zh) * | 2015-03-09 | 2019-04-16 | 常州制药厂有限公司 | 一种沙利度胺片及其制备方法 |
| CN106138052B (zh) * | 2015-04-16 | 2020-02-21 | 欣凯医药化工中间体（上海）有限公司 | 一种沙利度胺制剂及其制备方法 |
| JP2020533383A (ja) | 2017-09-14 | 2020-11-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 癌の組合せ治療 |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| KR102735378B1 (ko) | 2018-11-09 | 2024-11-27 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| AU2020370039B2 (en) * | 2019-10-21 | 2026-02-19 | Celgene Corporation | Pharmaceutical compositions comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same |
| IL300397A (en) | 2020-08-05 | 2023-04-01 | C4 Therapeutics Inc | Compounds for targeted knockdown of RET |
| JP2024544507A (ja) | 2021-11-09 | 2024-12-03 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | グルタルイミド母核を有するイソインドリノン誘導体及びその用途 |
| KR102823538B1 (ko) | 2021-11-09 | 2025-06-23 | 한국화학연구원 | 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도 |
| KR20240066904A (ko) | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | 아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
| KR20240066906A (ko) | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1531492A (en) | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
| US6114355A (en) | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
| US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5405855A (en) | 1993-12-23 | 1995-04-11 | Andrulis Pharmaceuticals Corp. | Treatment of insulin resistant diabetes with thalidomine |
| US5434170A (en) | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
| US6001828A (en) | 1995-06-05 | 1999-12-14 | Andrulis, Jr.; Peter | Use of tumor factor inhibitors together with antiviral agents and therapeutic compositions thereof against HIV infection |
| US5643915A (en) * | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
| US5731325A (en) | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
| US5654312A (en) | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
| ATE493983T1 (de) | 1996-11-05 | 2011-01-15 | Childrens Medical Center | Thalidomide und dexamethason für die behandlung von tumors |
| CA2319872C (en) * | 2000-02-02 | 2012-06-19 | Chun-Ying Huang | Pharmaceutical composition for the treatment of hepatocellular carcinoma |
| KR20030003708A (ko) * | 2000-03-31 | 2003-01-10 | 셀진 코포레이션 | 시클로옥시게나제-2 활성의 저해 |
| EP1286671B1 (en) * | 2000-05-15 | 2006-04-05 | Celgene Corporation | Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan |
| AU2003222034A1 (en) * | 2002-03-20 | 2003-10-08 | Celgene Corporation | (-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
-
2003
- 2003-06-30 US US10/608,077 patent/US7230012B2/en not_active Expired - Lifetime
- 2003-11-13 BR BR0316240-0A patent/BR0316240A/pt not_active IP Right Cessation
- 2003-11-13 KR KR1020057008631A patent/KR100671366B1/ko not_active Expired - Fee Related
- 2003-11-13 MX MXPA05005162A patent/MXPA05005162A/es active IP Right Grant
- 2003-11-13 CN CN201010115035A patent/CN101816626A/zh active Pending
- 2003-11-13 JP JP2004553785A patent/JP5269280B2/ja not_active Expired - Lifetime
- 2003-11-13 NZ NZ540545A patent/NZ540545A/en not_active IP Right Cessation
- 2003-11-13 SI SI200332255T patent/SI1562556T1/sl unknown
- 2003-11-13 EP EP10175930A patent/EP2277512A3/en not_active Withdrawn
- 2003-11-13 AU AU2003290982A patent/AU2003290982C1/en not_active Expired
- 2003-11-13 CN CN200380108803.9A patent/CN1738607B/zh not_active Expired - Fee Related
- 2003-11-13 CA CA002505964A patent/CA2505964C/en not_active Expired - Lifetime
- 2003-11-13 ES ES03783567T patent/ES2403142T3/es not_active Expired - Lifetime
- 2003-11-13 PT PT37835675T patent/PT1562556E/pt unknown
- 2003-11-13 EP EP03783567A patent/EP1562556B1/en not_active Expired - Lifetime
- 2003-11-13 DK DK03783567.5T patent/DK1562556T3/da active
- 2003-11-13 WO PCT/US2003/036620 patent/WO2004045579A2/en not_active Ceased
- 2003-11-14 TW TW096113473A patent/TWI377062B/zh not_active IP Right Cessation
- 2003-11-14 TW TW092132008A patent/TWI359659B/zh not_active IP Right Cessation
-
2005
- 2005-05-15 IL IL168585A patent/IL168585A/en active IP Right Grant
- 2005-05-16 ZA ZA200503927A patent/ZA200503927B/en unknown
-
2009
- 2009-05-15 JP JP2009119084A patent/JP4927905B2/ja not_active Expired - Fee Related
-
2010
- 2010-05-13 AU AU2010201931A patent/AU2010201931A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006508983A5 (https=) | ||
| ATE493130T1 (de) | Opioid enthaltende arzneiform gegen missbrauch | |
| JP2003520232A5 (https=) | ||
| JP2004155791A5 (https=) | ||
| JP2010518028A5 (https=) | ||
| JP2012031147A5 (https=) | ||
| CA2651588A1 (en) | Dry powder inhalation device for the simultaneous administration of more than one medicament | |
| JP2007510736A5 (https=) | ||
| JP2015511635A5 (https=) | ||
| JP2012533559A5 (https=) | ||
| JP2009537554A5 (https=) | ||
| JP2006514100A5 (https=) | ||
| JP2008516004A5 (https=) | ||
| RU2007107368A (ru) | Композиция, содержащая десмопрессин | |
| ES2172481A1 (es) | Composicion farmaceutica que contiene citalopram. | |
| JP2008515980A5 (https=) | ||
| RU2004131213A (ru) | Лекарственные формы трамадола замедленного высвобождения | |
| JP2019517536A5 (https=) | ||
| JP2015129175A5 (https=) | ||
| JP2002538207A5 (https=) | ||
| JP2008503445A5 (https=) | ||
| TNSN06003A1 (en) | Saquinavir mesylate oral dosage form | |
| PT1858494E (pt) | Nova cápsula de gelatina mole | |
| JP2006511543A (ja) | 安定なトピラメート製剤 | |
| JP2013528213A5 (https=) |